Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Alcohol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | FNTA | P49354 | 1/20 | 0.49 |
| ▸ | FNTB | P49356 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.47 |
| ▸ | FEN1 | P39748 | 1/20 | 0.47 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.47 |
| ▸ | BCL2 | P10415 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31722027 | 0.76 | SMN1; SMN2 (0.71) | SMN1; SMN2ALDH1A1AGTR1RAB9AHPGD | |
| SCHEMBL5796774 | 0.76 | MAPT (0.48) | SMN1; SMN2ALDH1A1AGTR1RAB9AHPGD | |
| SCHEMBL11257944 | 0.75 | FFAR1 (0.71) | ALDH1A1HPGDL3MBTL1KMT2AEPHX2 | |
| SCHEMBL593746 | 0.75 | AKR1C3 (0.73) | SMN1; SMN2ALDH1A1AGTR1RAB9AHPGD | |
| SCHEMBL19707558 | 0.74 | RAB9A (0.69) | SMN1; SMN2ALDH1A1AGTR1RAB9AHPGD | |
| SCHEMBL8805616 | 0.74 | ALDH1A1 (0.64) | SMN1; SMN2ALDH1A1AGTR1RAB9AHPGD | |
| SCHEMBL6201893 | 0.74 | ALDH1A1 (0.59) | SMN1; SMN2ALDH1A1AGTR1RAB9AHPGD | |
| SCHEMBL11805893 | 0.74 | RAB9A (0.65) | SMN1; SMN2ALDH1A1AGTR1RAB9AHPGD | |
| SCHEMBL1622815 | 0.73 | FFAR1 (0.59) | SMN1; SMN2ALDH1A1RAB9ANPC1MAPT | |
| Ethyl Chloride SCHEMBL1241195 | 0.73 | MAPT (0.62) | SMN1; SMN2ALDH1A1AGTR1HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050222264-A1 | Anti-rhinovirus active agents | UNIHART CORPORATION (IE) | 2005-10-06 | — | — | US | claimed |
| EP-1501492-A1 | ANTI-RHINOVIRUS ACTIVE AGENTS | Unihart Corporation (IE) | 2005-02-02 | — | — | EP | claimed |
| WO-2003094906-A1 | ANTI-RHINOVIRUS ACTIVE AGENTS | UNIHART CORPORATION (IE) | 2003-11-20 | — | — | WO | claimed |
| US-20050222264-A1 | Anti-rhinovirus active agents | UNIHART CORPORATION (IE) | 2005-10-06 | — | — | US | disclosed |
| EP-1267858-B1 | DIPHENYL KETOALDEHYDE DERIVATIVES WITH ANTI-HIV ACTIVITY | UNIHART CORP (IE) | 2004-07-28 | — | — | EP | disclosed |
| US-20040058999-A1 | Compounds with anti-hiv activity | UNIHART CORPORATION (IE) | 2004-03-25 | — | — | US | disclosed |
| US-4536517-A | ANTIDIABETIC, ANTILIPEMIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1985-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222264-A1 | Anti-rhinovirus active agents | GLO1, RNASEH1, GLB1 | SMN1; SMN2 4270/4885ALDH1A1 1357/4885AGTR1 1226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.